First Therapy Approved for Ultra-Rare Bone Disorder

(MedPage Today) -- The FDA approved the oral retinoid palovarotene (Sohonos) for treating abnormal bone growth associated with fibrodysplasia ossificans progressiva (FOP), drugmaker Ipsen announced on Wednesday. Palovarotene, a selective retinoic...
Source: MedPage Today Public Health - Category: American Health Source Type: news